Avrobio price target lowered to $19 from $27 at Leerink

Leerink analyst Mani Foroohar lowered his price target for Avrobio to $19 from $27, while reiterating a Market Perform rating on the shares. While the analyst is positive on recent additions to senior management, he is more conservative on the market opportunity for Fabry gene therapy given the need for higher-intensity preconditioning regimens than the company has used previously, and believes that the potential adoption of value-based annuity pricing models by the industry could pose further risk to Avrobio’s bottom line.
https://thefly.com/landingPageNews.php?id=2850161